Emergent BioSolutions Inc.

Form 4

Common

Common

Stock

Stock

Stock

November 2	21, 2006										
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION								ът	OMB APPROVAL		
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB Numbe	3235-0287			
Check this box if no longer subject to Section 16. Form 4 or				, ,	BENEF		L OV	VNERSHIP O	Estimat burden	Expires: January 31 2005 Estimated average burden hours per response 0.5	
Form 5 obligations may continue. See Instruction 1(b).  Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type	Responses)										
1. Name and A El-Hibri Fu	2. Issuer Name <b>and</b> Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]					5. Relationship of Reporting Person(s) to Issuer					
(Last)	(First) (1	Middle)	3. Date of Earliest Transaction				•	(Cl	neck all applic	cable)	
			(Month/Day/Year) 11/17/2006					_X DirectorX 10% Owner _X Officer (give title Other (specify below)  President, CEO & Chairman			
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
GATTHER	SBURG, MD 208	19						Person			
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Secur	ities A	cquired, Disposed	of, or Benef	icially Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/D	Date, if	3. Transaction Code (Instr. 8)	4. Securit or(A) or Dis (D) (Instr. 3, 4	posed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	11/20/2006			C	86,312	A	( <u>1</u> )	86,312	D		
Common Stock								8,314,819 (2)	I	By Intervac, L.L.C.	
Common								4.065.042.(2)	T	By B: Di	

BioPharm,

By Biovac,

By Intervac

Managment,

L.L.C.

L.L.C.

4,065,043 (3) I

1,599,155 (4) I

719,275 (5)

L.L.C.

(9-02)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Der Sec	Fitle of ivative urity str. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact Code (Instr. 8)	1		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Am Underlying Sec (Instr. 3 and 4)	
		Security			Code V	' (A)	(D)	Date Exercisable	Expiration Date	Title	A N Sl
Sto Op	tion ght to	\$ 3.5	11/17/2006		M		86,312	<u>(6)</u>	05/25/2010	Class B Common Stock	
	nss B mmon ock	<u>(7)</u>	11/20/2006		M	86,312		(8)	<u>(7)</u>	Common Stock	
	nss B mmon ock	<u>(7)</u>	11/20/2006		С		86,312	(8)	<u>(7)</u>	Common Stock	
Sto Op	tion ght to	\$ 3.5 (9)	11/20/2006		С		129,470	<u>(10)</u>	05/25/2010	Class B Common Stock	1
Sto Op	tion ght to	\$ 3.5 (9)	11/20/2006		С	129,470		<u>(11)</u>	05/25/2010	Common Stock	1

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
	X	X					

Reporting Owners 2 El-Hibri Fuad 300 PROFESSIONAL DRIVE GAITHERSBURG, MD 20879 President, CEO & Chairman

## **Signatures**

/s/Daniel Abdun-Nabi, attorney in fact

11/21/2006

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Class B common stock converted into Common Stock on a 1-for-1 basis.
- Mr. El-Hibri holds with his wife, as tenants by the entirety, a 32.5% equity interest in Intervac, L.L.C. Intervac, L.L.C. is the direct owner of 8,314,819 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 2,702,316 shares.
- Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 4,065,043 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,632,991 shares.
- Mr. El-Hibri holds with his wife, as tenants by the entirety, a 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,599,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,426,446 shares.
- Mr. El-Hibri holds with his wife, as tenants by the entirety, a 31.11% equity interest in Intervac Management, L.L.C. Intervac (5) Management, L.L.C. is the direct owner of 719,275 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 223,767 shares.
- The option is vested with respect to 86,312 shares of Class B Common Stock covered thereby and will vest with respect to the remaining 129,470 shares in two equal installments on December 31, 2006 and December 31, 2007.
- (7) The Class B Common Stock was convertible into Common Stock on a 1-for-1 basis and had no expiration date.
- (8) The shares of Class B Common Stock were acquired on November 17, 2006.
- (9) The option to purchase Class B Common Stock converted into an option to purchase Common Stock on a 1-for-1 basis.
- (10) The option was granted on May 25, 2005. The option will vest with respect to 129,470 shares in two equal installments on December 31, 2006 and December 31, 2007.
- (11) The option will vest with respect to 129,470 shares in two equal installments on December 31, 2006 and December 31, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3